The case for universal newborn SMA screening across the UK — and where the four nations currently stand.
Motor neurons lost to SMA cannot be replaced. Once they're gone, they're gone. This is the core argument for newborn screening: if we can identify SMA before symptoms appear, treatment can begin before significant motor neuron loss — and outcomes are dramatically better.
Clinical trials in pre-symptomatic infants — including the NURTURE study (Spinraza) and SPR1NT study (Zolgensma) — have shown outcomes almost indistinguishable from unaffected peers. Children who would otherwise have been profoundly affected by Type 1 SMA are instead walking and attending school.
Newborn bloodspot screening — the "heel prick" test already given to every UK baby — can be extended to include SMA by adding an analysis to the existing sample taken at 5 days of age.
Scotland added SMA to its newborn bloodspot screening programme in 2021 — every baby born in Scotland is now tested for SMA within days of birth.
In England, a formal proposal for SMA newborn screening was submitted to the UK National Screening Committee (UK NSC) in early 2026. The UK NSC will consider the evidence and make a recommendation to ministers. If approved, implementation would then need to be planned and funded.
Wales and Northern Ireland are awaiting the outcome of the England review, as policy in these nations generally follows UK NSC recommendations.
All babies born in Scotland are screened for SMA as part of the newborn bloodspot programme.
Proposal submitted to UK NSC in early 2026. Review and recommendation pending.
Awaiting UK NSC recommendation and its application to Welsh NHS policy.
Awaiting UK NSC recommendation and its application to Northern Ireland policy.
SMA screening costs very little per baby tested. Early treatment costs far less than the lifelong support needed when SMA progresses untreated. Most importantly — every baby diagnosed early has a chance at a life transformed.
Follow campaign progress